{"id":8465,"date":"2024-10-21T09:45:02","date_gmt":"2024-10-21T14:45:02","guid":{"rendered":"https:\/\/fifarma.org\/?post_type=publicaciones&#038;p=8465"},"modified":"2024-10-29T09:04:25","modified_gmt":"2024-10-29T14:04:25","slug":"fifarma-patient-w-a-i-t-indicator-2024-latin-america","status":"publish","type":"publicaciones","link":"https:\/\/fifarma.org\/en\/publications\/fifarma-patient-w-a-i-t-indicator-2024-latin-america\/","title":{"rendered":"FIFARMA Patient W.A.I.T. Indicator 2024 \u2014 Latin America (ENG)"},"content":{"rendered":"\n<p>Improving the availability of innovative medicines in Latin America is a priority for all stakeholders in the healthcare system, especially policymakers, pharmaceutical manufacturers, and patients. Since 2004, the European pharmaceutical industry association (E.F.P.I.A.) has run the Patients W.A.I.T. (Waiting to Access Innovative Therapies) Indicator, enabling stakeholders to measure the availability rate of innovative medicines in 37 European countries. This study has been replicated to understand availability rate in eight Latin American Countries.<\/p>\n\n    <div class=\"xs_social_share_widget xs_share_url after_content \t\tmain_content  wslu-style-1 wslu-share-box-shaped wslu-fill-colored wslu-none wslu-share-horizontal wslu-theme-font-no wslu-main_content\">\n\n\t\t\n        <ul>\n\t\t\t        <\/ul>\n    <\/div> \n","protected":false},"author":24,"parent":0,"template":"","ano":[88],"idioma":[45],"etiquetas-publicacion":[172,28,173],"categoria-publicacion":[29],"class_list":["post-8465","publicaciones","type-publicaciones","status-publish","hentry","ano-88","idioma-english","etiquetas-publicacion-acceso","etiquetas-publicacion-medicamentos-innovadores","etiquetas-publicacion-wait","categoria-publicacion-reporte"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.7 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FIFARMA Patient W.A.I.T. Indicator 2024 \u2014 Latin America (ENG) - FIFARMA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fifarma.org\/en\/publications\/fifarma-patient-w-a-i-t-indicator-2024-latin-america\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FIFARMA Patient W.A.I.T. Indicator 2024 \u2014 Latin America (ENG)\" \/>\n<meta property=\"og:description\" content=\"Improving the availability of innovative medicines in Latin America is a priority for all stakeholders in the healthcare system, especially policymakers, pharmaceutical manufacturers, and patients. Since 2004, the European pharmaceutical industry association (E.F.P.I.A.) has run the Patients W.A.I.T. (Waiting to Access Innovative Therapies) Indicator, enabling stakeholders to measure the availability rate of innovative medicines in [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fifarma.org\/en\/publications\/fifarma-patient-w-a-i-t-indicator-2024-latin-america\/\" \/>\n<meta property=\"og:site_name\" content=\"FIFARMA\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-29T14:04:25+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/fifarma-patient-w-a-i-t-indicator-2024-latin-america\\\/\",\"url\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/fifarma-patient-w-a-i-t-indicator-2024-latin-america\\\/\",\"name\":\"FIFARMA Patient W.A.I.T. Indicator 2024 \u2014 Latin America (ENG) - FIFARMA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#website\"},\"datePublished\":\"2024-10-21T14:45:02+00:00\",\"dateModified\":\"2024-10-29T14:04:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/fifarma-patient-w-a-i-t-indicator-2024-latin-america\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/fifarma-patient-w-a-i-t-indicator-2024-latin-america\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/fifarma-patient-w-a-i-t-indicator-2024-latin-america\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/fifarma.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publicaciones\",\"item\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"FIFARMA Patient W.A.I.T. Indicator 2024 \u2014 Latin America (ENG)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#website\",\"url\":\"https:\\\/\\\/fifarma.org\\\/\",\"name\":\"FIFARMA\",\"description\":\"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica\",\"publisher\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fifarma.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#organization\",\"name\":\"Fifarma\",\"alternateName\":\"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica\",\"url\":\"https:\\\/\\\/fifarma.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/logo-fifarma.png\",\"contentUrl\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/logo-fifarma.png\",\"width\":195,\"height\":39,\"caption\":\"Fifarma\"},\"image\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FIFARMA Patient W.A.I.T. Indicator 2024 \u2014 Latin America (ENG) - FIFARMA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fifarma.org\/en\/publications\/fifarma-patient-w-a-i-t-indicator-2024-latin-america\/","og_locale":"en_US","og_type":"article","og_title":"FIFARMA Patient W.A.I.T. Indicator 2024 \u2014 Latin America (ENG)","og_description":"Improving the availability of innovative medicines in Latin America is a priority for all stakeholders in the healthcare system, especially policymakers, pharmaceutical manufacturers, and patients. Since 2004, the European pharmaceutical industry association (E.F.P.I.A.) has run the Patients W.A.I.T. (Waiting to Access Innovative Therapies) Indicator, enabling stakeholders to measure the availability rate of innovative medicines in [&hellip;]","og_url":"https:\/\/fifarma.org\/en\/publications\/fifarma-patient-w-a-i-t-indicator-2024-latin-america\/","og_site_name":"FIFARMA","article_modified_time":"2024-10-29T14:04:25+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fifarma.org\/publicaciones\/fifarma-patient-w-a-i-t-indicator-2024-latin-america\/","url":"https:\/\/fifarma.org\/publicaciones\/fifarma-patient-w-a-i-t-indicator-2024-latin-america\/","name":"FIFARMA Patient W.A.I.T. Indicator 2024 \u2014 Latin America (ENG) - FIFARMA","isPartOf":{"@id":"https:\/\/fifarma.org\/#website"},"datePublished":"2024-10-21T14:45:02+00:00","dateModified":"2024-10-29T14:04:25+00:00","breadcrumb":{"@id":"https:\/\/fifarma.org\/publicaciones\/fifarma-patient-w-a-i-t-indicator-2024-latin-america\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fifarma.org\/publicaciones\/fifarma-patient-w-a-i-t-indicator-2024-latin-america\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fifarma.org\/publicaciones\/fifarma-patient-w-a-i-t-indicator-2024-latin-america\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/fifarma.org\/"},{"@type":"ListItem","position":2,"name":"Publicaciones","item":"https:\/\/fifarma.org\/publicaciones\/"},{"@type":"ListItem","position":3,"name":"FIFARMA Patient W.A.I.T. Indicator 2024 \u2014 Latin America (ENG)"}]},{"@type":"WebSite","@id":"https:\/\/fifarma.org\/#website","url":"https:\/\/fifarma.org\/","name":"FIFARMA","description":"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica","publisher":{"@id":"https:\/\/fifarma.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fifarma.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fifarma.org\/#organization","name":"Fifarma","alternateName":"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica","url":"https:\/\/fifarma.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fifarma.org\/#\/schema\/logo\/image\/","url":"https:\/\/fifarma.org\/wp-content\/uploads\/2022\/10\/logo-fifarma.png","contentUrl":"https:\/\/fifarma.org\/wp-content\/uploads\/2022\/10\/logo-fifarma.png","width":195,"height":39,"caption":"Fifarma"},"image":{"@id":"https:\/\/fifarma.org\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/publicaciones\/8465","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/publicaciones"}],"about":[{"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/types\/publicaciones"}],"author":[{"embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/users\/24"}],"wp:attachment":[{"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/media?parent=8465"}],"wp:term":[{"taxonomy":"ano","embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/ano?post=8465"},{"taxonomy":"idioma","embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/idioma?post=8465"},{"taxonomy":"etiquetas-publicacion","embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/etiquetas-publicacion?post=8465"},{"taxonomy":"categoria-publicacion","embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/categoria-publicacion?post=8465"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}